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follow-up study is designed to provide much-
needed safety data on potential late effects of 
ART in both mothers and children in Africa.
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Trial of ZMapp for Ebola Virus Infection
To the Editor: Davey and colleagues (Oct. 13 
issue)1 are to be commended for completing the 
ZMapp trial under challenging circumstances. 
However, in order to determine whether ZMapp 
represented the only difference across study 
groups, more detail should have been provided 
for the between-group comparisons. The ZMapp 
infusion protocol describes monitoring every 15 
to 30 minutes during early dose escalation1; how-
ever, no description exists for similar monitoring 
of the patients who received the standard of care. 
Frequent monitoring of patients receiving ZMapp 
may have resulted in earlier identification of seri-
ous adverse events and improved care delivery, an 
effect observed in other trials involving severe 
illness in similar settings.2 Elevated baseline cre-
atinine levels are associated with Ebola virus dis-
ease mortality.3,4 In the JIKI trial, the elevated 
baseline creatinine level was lethal in virtually all 
enrolled patients (97%) with a low cycle-threshold 
value for the virus (<20).5 In the ZMapp trial, pa-
tients receiving the standard of care appear to 
have had slightly higher baseline creatinine levels; 
it was not reported whether there was a signifi-
cant between-group difference. It is conceivable 
that such differences between study groups con-
tributed to the improved survival trend attributed 
to the ZMapp intervention.
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The authors reply: Jacob and Fletcher raise 
important issues of potential bias in assess-
ments of survival between the study groups, 
specifically citing differences in monitoring 
during follow-up and the possibility of chance 
imbalances in baseline creatinine levels. As ac-
knowledged in the Discussion section of the 
article, one limitation of the trial was its open-
label strategy (rather than a double-blind, pla-
cebo-controlled strategy), which may have in-
f luenced bedside monitoring during infusions. 
Accordingly, we cannot say whether the addi-
tional bedside monitoring provided some ben-
efit to ZMapp recipients that was independent 
of any effect of ZMapp itself. If so, however, it 
did not translate objectively into any differen-
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tial provision of daily measures of supportive 
care between groups (see Table S3 in the Sup-
plementary Appendix, available with the full 
text of the article at NEJM.org). Consonant with 
prevailing recommendations,1-3 P values for base-
line comparisons were not reported (Table 1 of 
our article). Consistent with other reports, 
higher baseline creatinine levels (>2 mg per 
deciliter vs. ≤2 mg per deciliter) were associated 
with an overall increased risk of death (crude 
odds ratio, 15.0; P = 0.004) in our trial. How-
ever, the inclusion of baseline creatinine levels 
(available for only 44 of 71 patients) as a co-
variate with location and polymerase-chain- 
reaction cycle threshold did not alter the odds 
ratio for mortality with ZMapp versus control 
(odds ratio, 0.21; 95% confidence interval [CI], 
0.03 to 1.48) from that without the inclusion of 
creatinine levels (odds ratio, 0.24; 95% CI, 0.04 
to 1.33).
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Von Willebrand’s Disease
To the Editor: In their review article on von 
Willebrand’s disease, Leebeek and Eikenboom 
(Nov. 24 issue)1 state that it is reasonable to mea-
sure both levels of factor VIII and ristocetin co-
factor activities during surgery in order to monitor 
the patient’s hemostatic response to replacement 
therapy with concentrates containing both von 
Willebrand factor and factor VIII. We think that 
levels of factor VIII alone should be measured 
because they are the best predictor of hemostasis 
in patients undergoing surgery.
Patients with alloantibodies to von Wille-
brand factor 2 have safely undergone surgery with 
the use of recombinant factor VIII that is devoid 
of von Willebrand factor.3,4 This indicates that 
the control of soft-tissue and surgical bleeding 
depends on factor VIII rather than on ristocetin 
cofactor levels, which remain unmeasurable in 
plasma throughout the postinfusion period be-
cause of the neutralizing action of alloantibod-
ies.3,4 Furthermore, levels of factor VIII increase 
more than would be predicted from the admin-
istered dose, owing to its endogenous stabiliza-
tion by the infused von Willebrand factor and 
accumulation of the factor VIII contained in 
concentrates. Thus, since evidence that surgical 
hemostasis depends on ristocetin cofactor levels 
is lacking, it is important to monitor levels of 
factor VIII after surgery.
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The authors reply: Mannucci and Franchini 
suggest that monitoring patients with von Wille-
brand’s disease during surgery should involve 
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